Get the Stockscreener App
73.99
0.14%
0.10
Pre-market:
74.00
0.01
+0.01%
Hologic Inc stock is traded at $73.99, with a volume of 5.16M.
It is up +0.14% in the last 24 hours and up +11.43% over the past month.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
See More
Previous Close:
$73.89
Open:
$73.91
24h Volume:
5.16M
Relative Volume:
2.08
Market Cap:
$16.46B
Revenue:
$4.04B
Net Income/Loss:
$557.10M
P/E Ratio:
30.70
EPS:
2.4102
Net Cash Flow:
$916.70M
1W Performance:
+5.93%
1M Performance:
+11.43%
6M Performance:
+26.93%
1Y Performance:
-8.55%
1-Day Range:
$73.87
$74.11
1-Week Range:
$71.49
$74.71
52-Week Range:
$51.90
$84.39
Hologic Inc Stock (HOLX) Company Profile
Name
Hologic Inc
Sector
Industry
Phone
(508) 263-2900
Address
250 CAMPUS DRIVE, MARLBOROUGH, MA
Compare HOLX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HOLX
Hologic Inc
|
73.99 | 16.45B | 4.04B | 557.10M | 916.70M | 2.4102 |
|
ISRG
Intuitive Surgical Inc
|
546.51 | 195.43B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
185.83 | 53.46B | 21.39B | 1.61B | 2.55B | 5.5609 |
|
RMD
Resmed Inc
|
259.49 | 38.71B | 5.15B | 1.40B | 1.65B | 9.5082 |
|
ALC
Alcon Inc
|
76.08 | 37.70B | 10.03B | 1.07B | 1.39B | 2.1549 |
|
WST
West Pharmaceutical Services Inc
|
297.47 | 22.09B | 2.96B | 487.70M | 344.00M | 6.6758 |
Hologic Inc Stock (HOLX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-18-25 | Upgrade | Argus | Hold → Buy |
| Aug-06-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| May-27-25 | Reiterated | Needham | Hold |
| Mar-03-25 | Downgrade | Argus | Buy → Hold |
| Feb-06-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-03-25 | Downgrade | Needham | Buy → Hold |
| Dec-13-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-10-24 | Initiated | Jefferies | Hold |
| Dec-10-24 | Reiterated | Needham | Buy |
| Oct-01-24 | Downgrade | Citigroup | Buy → Neutral |
| Jun-27-24 | Initiated | Stephens | Overweight |
| Apr-03-24 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-23 | Upgrade | Needham | Hold → Buy |
| Dec-07-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jul-20-22 | Downgrade | BofA Securities | Buy → Neutral |
| Jul-20-22 | Initiated | UBS | Neutral |
| Jul-18-22 | Downgrade | BTIG Research | Buy → Neutral |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-04-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Oct-14-21 | Initiated | Redburn | Neutral |
| Jul-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-20-20 | Downgrade | Needham | Buy → Hold |
| Nov-05-20 | Reiterated | Needham | Buy |
| Jun-30-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jun-03-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Apr-30-20 | Reiterated | Needham | Buy |
| Apr-30-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Apr-07-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-27-20 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-13-20 | Reiterated | Needham | Buy |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Sep-26-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Jan-31-19 | Reiterated | Needham | Buy |
| Jan-02-19 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Oct-09-18 | Initiated | UBS | Neutral |
| Sep-13-18 | Downgrade | BofA/Merrill | Buy → Neutral |
View All
Hologic Inc Stock (HOLX) Latest News
Real time breakdown of Hologic Inc. stock performanceWeekly Risk Report & Free Verified High Yield Trade Plans - newser.com
Hologic Inc. recovery potential after sell offQuarterly Market Summary & Verified Momentum Watchlists - newser.com
Will Hologic Inc. stock attract ESG investorsInflation Watch & AI Forecasted Stock Moves - newser.com
Hologic Inc. stock momentum explainedMarket Weekly Review & AI Driven Price Predictions - newser.com
Statistical indicators supporting Hologic Inc.’s strengthDividend Hike & Expert Approved Momentum Trade Ideas - newser.com
Best data tools to analyze Hologic Inc. stockJobs Report & Verified Short-Term Plans - newser.com
How Hologic Inc. (HO1) stock responds to bond marketWeekly Loss Report & Verified Momentum Watchlists - newser.com
Is Hologic Inc. (HO1) stock bottoming after sell offQuarterly Trade Review & High Accuracy Trade Alerts - newser.com
Women’s health could benefit from the private equity treatment - Financial Times
Key deals this week: United States Antimony, Grindr, Eli Lilly, Hologic and more - Seeking Alpha
Does Blackstone’s Hologic Deal and Earnings Shift the Long-Term Story for BX? - simplywall.st
Hologic Inc Stock (HOLX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.36%
0.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):